• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.

作者信息

Korman Tony M

机构信息

Centre for Inflammatory Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia

Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia.

出版信息

Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02489-20.

DOI:10.1128/AAC.02489-20
PMID:33288636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8092553/
Abstract
摘要

相似文献

1
Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.法匹拉韦与COVID-19早期门诊治疗的必要性
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02489-20.
2
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).非那韦和对 SARS-CoV-2 感染（COVID-19）早期门诊治疗的需求。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.02017-20.
3
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.口服法匹拉韦治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒RNA清除延迟患者：病例系列
Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.
4
Comment on: Favipiravir, an antiviral for COVID-19?关于：法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？的评论
J Antimicrob Chemother. 2021 Jan 1;76(1):279-280. doi: 10.1093/jac/dkaa378.
5
Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.关于《法匹拉韦治疗中重度新型冠状病毒肺炎的安全性和有效性》的评论
Int Immunopharmacol. 2022 Jan;102:107693. doi: 10.1016/j.intimp.2021.107693. Epub 2021 May 28.
6
Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.从一项法匹拉韦临床试验队列中分离的 SARS-CoV-2 的病毒学和基因组分析。
J Infect Chemother. 2021 Sep;27(9):1350-1356. doi: 10.1016/j.jiac.2021.06.010. Epub 2021 Jun 12.
7
Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.法匹拉韦治疗新型冠状病毒肺炎患者的临床疗效与安全性
J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2020.12.005. Epub 2020 Dec 7.
8
Bilateral foot ulcers in a COVID-19 patient under favipiravir treatment.一名接受法匹拉韦治疗的COVID-19患者出现双侧足部溃疡。
J Cosmet Dermatol. 2021 Aug;20(8):2390-2391. doi: 10.1111/jocd.14307. Epub 2021 Jun 28.
9
Alectinib, COVID-19 and favipiravir.阿来替尼、新型冠状病毒肺炎与法匹拉韦
J Oncol Pharm Pract. 2021 Oct;27(7):1810. doi: 10.1177/10781552211035823. Epub 2021 Aug 23.
10
Favipiravir Induced Nephrotoxicity in Two Patients of COVID-19.法匹拉韦在两名新冠肺炎患者中引起肾毒性。
J Assoc Physicians India. 2021 Jan;69(1):90.

本文引用的文献

1
Hydroxychloroquine for coronavirus: how not to repurpose a drug during a pandemic.用于治疗冠状病毒的羟氯喹：疫情期间如何避免不当药物再利用。
Intern Med J. 2020 Nov;50(11):1307-1310. doi: 10.1111/imj.15064. Epub 2020 Oct 30.
2
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.一项针对 COVID-19 感染的抗病毒药物的适应性随机安慰剂对照 II 期试验（VIRCO）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 13;21(1):847. doi: 10.1186/s13063-020-04766-5.
3
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.高剂量的法匹拉韦对感染 SARS-CoV-2 的仓鼠具有强大的抗病毒活性，而羟氯喹则没有活性。
Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955-26965. doi: 10.1073/pnas.2014441117. Epub 2020 Oct 9.
4
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
5
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).非那韦和对 SARS-CoV-2 感染（COVID-19）早期门诊治疗的需求。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.02017-20.
6
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.一项关于法匹拉韦早期与晚期治疗对COVID-19住院患者疗效的前瞻性、随机、开放标签试验。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01897-20.
7
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.羟氯喹联合或不联合阿奇霉素对 COVID-19 患者死亡率的影响：系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Jan;27(1):19-27. doi: 10.1016/j.cmi.2020.08.022. Epub 2020 Aug 26.
8
Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19.对《COVID-19 高风险门诊患者羟氯喹和阿奇霉素联合治疗的专论》的担忧。
Am J Epidemiol. 2021 Apr 6;190(4):491-495. doi: 10.1093/aje/kwaa189.
9
Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients.新出现的临床前证据不支持在新冠肺炎患者中广泛使用羟氯喹。
Nat Commun. 2020 Aug 26;11(1):4253. doi: 10.1038/s41467-020-17907-w.
10
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.阿维福韦治疗中度 2019 冠状病毒病（COVID-19）患者：一项 II/III 期多中心随机临床试验的中期结果。
Clin Infect Dis. 2021 Aug 2;73(3):531-534. doi: 10.1093/cid/ciaa1176.